Physician profile
Clay A Carter
NPI 1639726938
$2,392.61
in general payments reported to CMS, 2019-2025
15 companies · $1,183 in 2025
The $1,183 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $59.27 · 2023: $499 · 2024: $651 · 2025: $1,183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,143 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,143.35 |
| Education | $189.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $636.37 | 2025 | Nemluvio |
| Janssen Biotech, INC. | $469.49 | 2022-2024 | Tremfya |
| Abbvie INC. | $331.84 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $273.69 | 2022-2025 | Dupixent |
| Genzyme Corporation | $144.85 | 2023-2025 | |
| Arcutis Biotherapeutics, INC. | $115.66 | 2023-2025 | Zoryve |
| Incyte Corporation | $70.96 | 2024-2025 | Opzelura |
| Lilly USA, LLC | $62.65 | 2024-2025 | Taltz, Olumiant, Ebglyss |
| Leo Pharma INC. | $55.68 | 2023-2024 | Adbry |
| Novartis Pharmaceuticals Corporation | $50.02 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.16 | 2024-2025 | Spevigo |
| Gilead Sciences, INC. | $47.28 | 2024 | |
| Organogenesis INC. | $41.00 | 2024 | Affinity |
| Organon LLC | $27.54 | 2023-2025 | Hadlima, Vtama |
| Amgen INC. | $16.42 | 2025 | Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clay Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.